Dawson James analyst Jason Kolbert downgraded Hillstream BioPharma to Neutral from Buy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HILS:
- Hillstream BioPharma appoints Sireesh Appajosyula as COO
- Hillstream BioPharma announces strategic reprioritization of pipeline
- Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics
- Hillstream BioPharma licenses technology for proprietary antibody conjugates
- Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers